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Summary
Objective: Viscosupplementation with hylan G-F 20 has recently become registered for treatment of patients with osteoarthritis (OA) of the
knee in most parts of the world. The cost effectiveness and cost utility of this new therapeutic modality were determined as part of a Canadian
prospective, randomized, 1-year, open-label, multicentered trial.
Design: A total of 255 patients were randomized to ‘Appropriate care with hylan G-F 20’ (AC+H) or ‘Appropriate care without hylan G-F 20’
(AC). Costs (1999 Canadian dollars) were collected from the societal viewpoint and included all costs related to OA of the knee and OA in
all joints. Patients completed a number of outcomes questionnaires including the Western Ontario and McMaster Universities Osteoarthritis
Index (WOMAC) and the Health Utilities Index Mark 3 (HUI3). Data were collected at clinic visits (baseline, 12 months) and by telephone
(1, 2, 4, 6, 8, 10, and 12 months).
Results: The AC+H group over the year had higher costs ($2125–$1415=$710, P<0.05), more patients improved (69%–40%=29%,
P=0.0001), greater increases in HUI3 (0.13–0.03=0.10, P<0.0001) and increased quality-adjusted life years (QALYs) (0.071, P<0.05). The
incremental cost-effectiveness ratio was $2505/patient improved. The incremental cost–utility ratio was $10 000/QALY gained. Sensitivity
analyses and a second cost perspective gave similar results.
Conclusion: The cost–utility ratio is below the suggested Canadian adoption threshold. The results provide strong evidence for adoption of
treatment with hylan G-F 20 in the patients and settings studied in the trial. © 2002 OsteoArthritis Research Society International. Published
by Elsevier Science Ltd. All rights reserved.
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Hylan G-F 20 (Synvisc® Genzyme Corporation, Cambridge,
MA, U.S.A.) is a high-molecular weight viscosupplemen-518tation product for injection into the intraarticular space of
the knee as a synovial fluid replacement. The product has
molecular weight and viscosity similar to the synovial fluid
found in healthy knees1. Hylan G-F 20 has been recently
approved for the treatment of patients with osteoarthritis
(OA) of the knee in most countries in the world. Accordingly,Received 28 June 2001; revision requested 5 November 2001;revision received 22 November 2001; accepted 6 December 2001.
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STUDY DESIGN
This was a multicenter, 1-year, prospective, randomized,
open-label, parallel design trial of appropriate care with
hylan G-F 20 (AC+H) compared to appropriate care with-
out hylan G-F 20 (AC) in the treatment of patients with
symptomatic OA of the knee. Patients were recruited from
14 sites across Canada, 10 rheumatologists and four
orthopedic surgeons. Patients had to be older than 40years of age, to have a primary diagnosis of radiologically
verified OA in the study knee (knee most symptomatic or
with the most predominant musculoskeletal problem),
excluding grade IV; to be symptomatic (total pain score
greater than 175 mm on the five 100 mm visual analogue
pain questions in the Western Ontario McMaster University
Osteoarthritis Index (WOMAC)8 despite prior treatment
with acetaminophen or non-steroidal antiinflammatory
drugs (NSAIDS) at any point prior to the study, and to be
ambulatory.
Protocol-driven costs and outcomes were minimized by
limiting study-induced clinic visits. Patients were assessed
at the site during the baseline visit and the 12-month
termination visit. Patients randomized to AC+H returned to
the site for 2 consecutive weeks after baseline for the
remaining hylan G-F 20 injections. Other visits could occur
on an ‘as needed’ basis for clinical deterioration, treatment
of adverse events, change in medication, or additional
treatment with hylan G-F 20 if required; however, no other
visits were required by the protocol.
Structured telephone interviews of the patients in both
treatment groups were conducted by the CRO at 1, 2, 4, 6,
8, 10, and 12 months. The 12-month termination visit was
included for patient assessment by the investigator and
for measuring change since baseline. At the baseline visit
the following data were collected: patient demographics,
appropriate care treatment for knee OA, treatment for
overall OA, concomitant medications, and patient self-
administered questionnaires (WOMAC Likert 3.0)8 4-week
recall, the Short-Form 36 (SF-36)9 4-week recall, and the
Health Utilities Index 3 (HUI3)10 4-week recall. Except for
patient demographics, the same information was collected
at each telephone interview, with the addition of pill counts,
adverse events, health care resources (e.g., physician
visits, physiotherapy, hospitalizations), any patient
expenses (e.g., travel), and lost time from work or usual
activities due to OA treatment or OA symptoms. At each
telephone interview the information was collected for the
time period since the last interview, except for the patient
self-administered questionnaires at months 4, 6, 8 and 12
where the recall period was 4 weeks. During the telephone
interviews, the patient referred to the self-administered
questionnaire and provided his/her answers to the tel-
ephone interviewer. To blind the patient to his/her previous
answers to the same questions, s/he was instructed not to
record the answers, and the questionnaire was laminated
with plastic to make it difficult if someone tried to do so.
Information collected during the telephone interviews (with
the exception of the questionnaires) was compared with
the patient’s medical chart during monitoring visits and
differences were resolved. The investigator reviewed
the adverse events for possible attribution to study
interventions.OUTCOME MEASURES
The WOMAC Likert 3.0 is a disease-specific HRQOL
instrument that asks the patient questions concerning the
study knee. It produces an aggregate total score and
scores for three subscales: pain, stiffness and physical
functioning.
The outcome measure for the cost-effectiveness analy-
sis (CEA) was patients improved. In the design of the study
the Steering Committee provided two definitions of an
improved patient. The primary definition was a patient
whose WOMAC pain score at month 12 was reduced bythe question we sought to answer in this research project
was, given that this is an approved and used treatment,
how effective and cost effective is it in the real world
compared to appropriate care without its availability? That
is, we sought to compare a world with hylan G-F 20 to a
world without hylan G-F 20.
Health-related quality of life (HRQOL), effectiveness,
cost-effectiveness and cost–utility are studied and reported
here. The clinical and safety results of this study are
reported in the accompanying manuscript2. The study was
conducted following the Canadian guidelines for health
economic studies3, which in turn are consistent in most
respects with similar guidelines in other countries4–6. This
is a pragmatic trial. To enhance the real world generaliz-
ability of the results the study was conducted in multiple
sites, with both rheumatologists and orthopedic surgeons,
the study was 1 year in length, the inclusion/exclusion
criteria were liberal, and the study was not blinded. The
comparator was deliberately selected as appropriate care,
not usual care. It was felt that usual care might contain
some inappropriate care, and demonstrating that a new
treatment is effective and cost-effective compared to in-
appropriate care is not particularly useful. Appropriate
care is the preferred management strategy of specialists,
rheumatologists or orthopedic surgeons, encouraged to
follow the treatment guidelines published by the American
College of Rheumatology7, and instructed to treat
conservatively.
The study was funded jointly by Biomatrix, Inc and
Rhoˆne-Poulenc Rorer Canada Inc. Innovus Research Inc.,
an independent contract research organization (CRO), was
contracted to manage the study. An independent Steering
Committee was assembled with the responsibility to design
the study, develop the analysis plan, and disseminate study
results. The Committee consisted of five academics, one
representative from each of the two sponsoring companies
and one representative from the CRO. The Steering Com-
mittee was deliberately structured to be dominated by the
five independent academics on the Committee. The Steer-
ing Committee was very active and, in fact, dealt with all
scientific questions that arose throughout the course of the
study, and did so blinded to implications. The contractual
arrangement gave the investigators unrestricted rights to
publish the study results.
There are several audiences for the study. Clinicians will
be interested in the findings of clinical effectiveness and of
HRQOL. Many clinicians will also be interested in the
findings of the cost-effectiveness and cost–utility analyses,
particularly clinicians interested in the efficient use of lim-
ited resources and those involved in establishing treatment
guidelines. Third-party payers, formulary managers, and
fiscal administrators will be interested in all of the findings
but particularly the results of the cost-effectiveness and
cost–utility analyses.
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definition was a patient who not only reduced their pain
score by 20% or greater but also reduced either their
stiffness or their physical functioning score by 20% or more
as well. The design also specified that the percentage of
patients improved in the AC+H group would have to
exceed the percentage in the AC group by at least 20% for
the results to be clinically important.
The HUI3 is a generic, preference-weighted health
status instrument that asks the patient questions about
their overall health status and HRQOL. Specifically, the
HUI3 measures health status using the following eight
attributes: vision, hearing, speech, ambulation, dexterity,
emotion, cognition and pain/discomfort. The patient is clas-
sified on each attribute into a level varying from normal to
severely impaired. The scoring formula for the instrument is
based on community preferences as measured by the
standard gamble method and thus represents a von
Neumann–Morgenstern utility11. The instrument provides
an overall utility score (min: −0.36; max: 1) on the conven-
tional health utility scale where dead=0.00 and perfect
health=1.00. States worse than death can take on negative
scores.
The outcome measure for the cost-utility analysis (CUA)
is the number of quality-adjusted life years (QALY) gained.
The overall utility score from the HUI3 is used as the quality
adjustment factor for calculating QALYs gained. Note that
the cost-effectiveness analysis focuses on the study knee
effectiveness, whereas the cost-utility analysis focuses on
patient effectiveness.PERSPECTIVES
Figure 1 shows the categories of costs that are included
in the different perspectives. Some costs, such as medi-
cations and hylan G-F 20, fall in more than one perspective,
depending upon the patient’s drug plan. A comprehensive
societal perspective was adopted as the primary perspec-
tive for the economic analyses. In this perspective all costs
are counted. Lost time was captured for both the patient
and for the unpaid family caregiver, and was categorized
into lost work time (for those in paid employment) and lost
usual activity time (for those not in paid employment). In the
base case analysis only lost work time was included. In a
sensitivity analysis, all lost time was included. The health
care system (HCS) consists of the two major payers in
Ontario, Ministry of Health and private medical plans. This
perspective was adopted as the secondary perspective.RESOURCE UTILIZATION AND COSTING
At each telephone interview patients reported health
care received, and indicated which they thought were
related to OA (i.e., due to OA in any joint, the treatment of
OA in any joint, or the treatment of adverse events related
to the treatment of OA). The patient’s data were compared
with the patient’s chart at the investigator’s office, and
discrepancies were resolved. The physician or the
research coordinator at the site reviewed the items and
could override the patient’s attribution to OA. To improveFig. 1. The types of costs that were included in the societal and health care system perspectives.
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from the Steering Committee reviewed the attribution of all
resources, while blinded to treatment allocation. They could
override the site’s attribution to OA. Only costs related to
OA were included in the analysis. The following protocol
driven items were not included in the costs: screening visit,
X-ray at screening, lab test at baseline, and termination
visit.
Costs are reported in 1999 Canadian dollars ($Can).
Costs not available in 1999 dollars were adjusted to 1999
using the health and personal care component of the
consumer price index12. Costs are from the province of
Ontario, Canada’s largest province.
The market price of hylan G-F 20 in Canada during the
study was $339 including tax per course of three injections.
Medications were priced according to the Best Available
Price for drugs listed on the Ontario Drug Benefit Formu-
lary, or the brand name price from a pharmacy wholesaler’s
catalogue13,14. Prices for outpatient resources were
obtained from a variety of appropriate sources; e.g., fees
for physician services and laboratory and procedures15,
and cost of other health care professionals16. A standard
cost ($165.55) for a generic emergency room (ER) visit was
used for all ER visits in the study16. The reason for
hospitalization (e.g. total knee replacement) was coded into
an international classification of disease ninth revision
clinical modification (ICD9-CM) code. The mean cost for
patients hospitalized for that ICD9-CM code for the same
length of stay was employed17. Patient lost productivity
was valued at the Canadian average industrial wage rate
($121.59 per day) for time lost from employment and
non-work time losses18.STATISTICS
The sample size for the study was calculated based on
the primary effectiveness measure for the clinical results,
mean change in WOMAC pain score in study knee, as
described in the accompanying paper2. The sample size
was not calculated on the basis of the cost-effectiveness or
cost–utility ratio because well-established methods to do so
did not exist at the time the study was designed.All patients randomized were included in the analysis.
Missing data were imputed, so that a full data set was
available for the statistical analyses. The hot deck method
was used to impute data19. A patient with missing data was
matched to a small group of ‘similar’ patients with complete
data, from which one was selected randomly. Data points
missing in the index patient were filled in from the matched
patient. Consistent with the comparison of a world with
hylan G-F 20 to a world without hylan G-F 20, the few
patients in the AC group who violated the protocol by
receiving hylan G-F 20 treatment were treated as drop-outs
at that point2. That is, their data from that point forward
were imputed, just like any other drop-out.
The WOMAC and HUI3 questionnaires specified a recall
period of 4 weeks, except for the questionnaires at months
1 and 2 in which the recall period was the time since the
previous visit. The HUI3 overall utility score represents the
mean score for that patient over the recall time period. A
typical patient profile is shown in Fig. 2. Note, the horizontal
segments in Fig. 2 represent measured scores while the
sloping segments represent linear interpolation. The QALY
for each patient is calculated by taking the area under the
curve for the patient’s utility, using years as the unit for
time.
Because all patients were not in the study for exactly
365 days, their costs and QALYs were converted to an
equivalent annual figure [annualized cost or QALY=(total
cost or QALY for time in study/number of days on
study)×365.25 days]. Because the time horizon for the
analysis was 1 year, discounting of future costs and
consequences was not necessary.
The base case analysis is the primary analysis. The
following one-way sensitivity analyses were performed to
test the robustness of the results:
• Effectiveness: for the CEA, the incremental effectiveness
(difference in proportion of patients improved) was varied
to its upper and lower 90% confidence bounds. Similarly,
for the CUA, the incremental effectiveness (QALYs
gained) was varied to its upper and lower 90% confi-
dence bounds.
• Cost: for the CEA and CUA, the incremental cost was
varied to its upper and lower 90% confidence bounds.0 12
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ig. 2. A typical patient profile for the HUI3 score showing the area-under-the-curve calculation for quality-adjusted life years (QALY). The
baseline HUI3 score is shown on the y-axis; however, it is not used to calculate the QALY.
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liberal costing of time loss that costed all time loss
whether work or usual major activity (including leisure). In
the base case only time loss from work was costed.ResultsPATIENTS
One hundred and twenty-seven patients were random-
ized to receive AC+H and 128 to receive AC. The
demographic and OA status of the patients are displayed in
Table I. The patients had a mean age of 63 years, with the
preponderance of them being unemployed women with OA
in both knees, and covered by a drug plan. The two groups
were well balanced.COSTS
The mean annual OA-related cost per patient from the
societal perspective by type of cost is shown in Table II.
There were too many different kinds of costs to show unit
costs within type (e.g. 20 types of injections, 80 types of
outpatient resources, 30 types of assistive devices). The
total annual cost per patient in a world without hylan G-F 20
(AC group) was $1415. The total in a world with hylan G-F
20 was $2125, an excess of $710. The 95% confidenceTable I
Demographic information and osteoarthritis status, f (percent
of n)*
AC+H
(n=127)
AC
(n=128)
Age, mean (S.D.) years 62.6 (9.4) 63.5 (10.5)
Sex, female 86 (68%) 93 (73%)
Work status
Full-time 30 (24%) 19 (15%)
Part-time 11 (9%) 16 (13%)
Sick leave 1 (1%) 2 (2%)
Not in paid employment 84 (66%) 90 (70%)
Not specified 1 (1%) 1 (1%)
Prescription drug plan coverage
No plan 15 (12%) 15 (12%)
Employer or private 53 (41%) 39 (31%)
Government 47 (37%) 64 (50%)
Government+(private or employer) 11 (9%) 8 (6%)
Not specified 1 (1%) 2 (2%)
Duration (years) of OA symptoms
Study knee, mean (S.D.) 9.0 (9.5) 9.9 (9.7)
Other knee, mean (S.D.) 7.4 (8.8) 8.3 (9.3)
OA at baseline
Other knee affected 109 (86%) 108 (84%)
Other joints affected 86 (68%) 78 (61%)
*f is frequency, n is sample size. Not all percentages sum to 100
due to rounding.
OA=osteoarthritis; AC+H=Appropriate Care + hylan G-F 20;
AC=Appropriate Care.Table II
Mean annual OA-related cost per patient from the societal perspective
AC+H
(n=127)
AC
(n=128)
Mean
difference
([AC+H]−
AC)
hylan G-F 20 676.01 (370.89) 0.00 (0.00) 676.01
Knee OA appropriate care treatment
Injections (e.g. corticosteriods) 4.05 (10.42) 18.45 (17.31) −14.40
Medications (e.g. NSAIDs) 200.63 (242.95) 370.10 (529.13) −169.48
Other therapy (e.g. physiotherapy) 237.32 (831.22) 305.10 (669.22) −67.78
Assistive devices (e.g. cane) 5.38 (11.61) 16.38 (54.58) −11.00
Procedures (arthroscopy) 1.70 (19.19) 18.12 (118.65) −16.42
Subtotal (knee treatment) 449.08 728.15 −279.08
Concomitant medications
OA in other joints (e.g. NSAIDs) 16.91 (67.62) 17.81 (72.06) −0.90
Adverse events due to OA treatment (e.g. antacid, analgesics) 53.88 (179.05) 50.08 (123.68) 3.80
Subtotal (concomitant meds) 70.79 67.89 2.90
Outpatient resources (e.g. physician visits) 245.72 (399.96) 134.02 (135.11) 111.70
Hospitalization 194.53 (1012.28) 101.57 (752.54) 92.96
Time loss from work
by patient
Due to OA 229.13 (942.26) 190.37 (1085.09) 38.76
Due to OA treatment 53.49 (150.86) 37.95 (180.66) 15.54
by caregiver
Due to OA 0.37 (4.15) 0.06 (0.69) 0.31
Due to OA treatment 35.30 (350.30) 6.56 (26.32) 28.74
Subtotal (time loss) 318.29 234.94 83.35
Out-of-pocket expenses (e.g. transportation) 170.30 (250.09) 148.00 (215.23) 22.30
Total cost 2124.71 (2528.35) 1414.58 (2032.74) 710.13
All costs are in 1999 Canadian dollars. Mean (S.D.).
OA=osteoarthritis; AC+H=Appropriate Care+hylan G-F 20; AC=Appropriate Care; NSAIDs=non-steroidal antiinflammatory drugs.
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bound of $147 and an upper bound of $1273. Thus, the
cost difference between groups was statistically significant
at the 5% level (95% confidence interval did not include 0).
From a HCS perspective, the total annual OA-related cost
was also greater in the AC+H group, and by almost the
same amount. The difference was $705 which was also
statistically significant at the 5% level (data not shown).
The major contributor to the societal incremental cost of
$710 was the cost of the hylan G-F 20 itself, $676. This was
the average cost of hylan G-F 20 per patient over the year
in the AC+H group. The actual cost of the product for a
treatment of three injections was $339, but because many
patients had the other knee done as well, and some had
additional treatments throughout the year, the average cost
was $676. The second major contributor to the incremental
cost of $710 was a savings in other treatment costs for the
knee OA of $279 (Table II, knee OA appropriate care
treatment). The third major contributor was the $112 extra
for outpatient visits, primarily the visits to receive injections
of hylan G-F 20. At $93 hospitalizations were the next
largest contributor. In the base case analysis there were a
total of five hospitalizations attributable to OA in the AC+H
group and three in the AC group. The five in the AC+H
group were: total knee replacement in study knee, total
knee replacement in other knee, total hip replacement,
triple ankle fusion, and tibia osteotomy. The three in the AC
group were: total knee replacement in study knee, total
knee replacement in other knee, and bunionectomy. Inter-
estingly, there were two additional total knee replacements
in the study knee that were not counted in the base case
analysis because they occurred after the two patients in
question had violated protocol by receiving hylan G-F 20.
The fifth largest contributor to the cost difference was the
additional cost of lost work time for the AC+H group at $83,
which could be due to the visits needed for the hylan G-F
20 injections. Out of pocket expenses were also slightly
higher possibly for the same reason, i.e., travel costs for
visits.CONSEQUENCES
The percent of patients improved at 12 months using the
primary definition of improvement was 69% in the AC+H
group and 40% in the AC group for an increment of
29%. Using the secondary definition of improvement the
results were 62% and 35% for an increment of 27%.
Both increments were statistically significant (P=0.0001)
and exceeded the clinically important difference of 20%
established a priori as part of the research design.
The improvement in mean utility from baseline to termin-
ation as measured by the HUI3 was 0.13 in the AC+H
group compared to 0.03 in the AC group, for a difference of
0.10 units of utility (P<0.0001). Figure 3 displays the
change in mean utility score from baseline to each inter-
view for both treatment groups. Both groups improved
sharply for the first 2 months and then tailed off. However,
the AC+H group improved more and tailed off less, thus
giving a substantial area between the two curves. The area
between the two curves over the 12 months represents the
difference in QALYs between the two groups. The patients
in the AC+H group gained 0.071 QALYs compared to the
patients in the AC group. The 95% confidence interval for
the difference in QALYs was a lower bound of 0.017 and an
upper bound of 0.126. The difference between groups was
statistically significant at the 5% level (95% confidence
interval did not include 0).BASE CASE ANALYSIS
The base case CEA and CUA are shown in the first row
of Table III. The AC+H group was more costly and more
effective. The incremental cost per patient over 1 year was
$710 and $705 from the societal and HCS perspective,
respectively. The incremental effectiveness was an
increase of 0.2834 proportion of patients improved. The
C/E ratio was $2505 or $2488 per patient improved, from
the societal and HCS perspective, respectively. For the
CUA the incremental effectiveness was 0.071 QALYs
per patient. The C/U ratio was $10 000 or $9930 per
QALY gained, from the societal and HCS perspective,
respectively.SENSITIVITY ANALYSES
Table III displays the results of the sensitivity analyses
for the CEA and CUA. There are five sensitivity analyses:
effectiveness high, effectiveness low, costs high, costs low,
and alternative definition of lost time. To help interpret these
results the CUA sensitivity analyses are plotted on a
cost-effectiveness graph in Fig. 4. Note that the slope of the
line through the point is the cost per QALY of that point.
Thus, lower slopes are more cost-effective, and vice versa.
To enhance the interpretation we have also plotted on Fig.
4 the decision thresholds suggested by Laupacis et al.20:
cost per QALY between $0 and $20 000=strong evidence
for adoption; between $20 000 and $100 000=moderate
evidence for adoption; and above $100 000=weak evi-
dence for adoption. Figure 4 demonstrates that the results
are robust; four of the five sensitivity analyses fall in the
decision sector ‘strong evidence for adoption’ while the
fifth falls in the adjacent sector ‘moderate evidence for
adoption’.Discussion
Although the trial was powered only for the primary
clinical outcome (change in mean WOMAC pain score), the
outcomes for the economic evaluation (gain in percent of
patients improved, gain in QALYs, and cost difference) also
achieved statistical significance at the 5% level. Thus the
findings are particularly robust, especially for a prospective
economic evaluation study.0.00
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of hylan G-F 20 reduced the need for and the cost of other
treatments for OA, but not enough to offset the increased
costs due to the price of the product and due to thecosts associated with the extra physician visits required to
administer the treatment.
The patient outcome findings are also straightforward.
The patients in the AC+H group were better off, and0 0.12
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cost of time loss from work or usual major activity for all patients and caregivers. CI=confidence interval; QALY=quality-adjusted life year;
$Can=Canadian dollars.Table III
Cost-effectiveness and cost–utility analyses: base case and sensitivity analyses from the societal and health care system perspectives
Annual cost
difference
Difference in
proportion of
patients
improved
Cost per patient
improved*
QALYs
gained†
Cost per QALY
gained‡
Societal HCS Societal HCS Societal HCS
Number of patients (AC+H/AC)§ 127/128 127/128 127/127 127/128 127/128 127/128 127/128 127/128
Base-case analysis $710 $705 0.2834 $2505 $2488 0.071 $10 000 $9930
Sensitivity analyses on outcomes\
High $710 $705 0.3820 $1859 $1846 0.117 $6068 $6026
Low $710 $705 0.1848 $3842 $3815 0.025 $28,400 $28,200
Sensitivity analyses on costs\
High $1183 $1008 0.2834 $4174 $3557 0.071 $16,662 $14,197
Low $238 $402 0.2834 $840 $1418 0.071 $3352 $5662
Sensitivity analysis using alternative
costing for time loss** $938 n/a†† 0.2834 $3310 n/a†† 0.071 $13,211 n/a††
All costs are in 1999 Canadian dollars.
*The cost per patient improved=incremental cost ([AC+H]−AC)/incremental effectiveness ([AC+H]−AC).
†QALY gained is adjusted for baseline differences.
‡The cost per QALY gained=incremental cost ([AC+H]−AC)/incremental QALY ([AC+H]−AC).
§The mean cost per patient and QALYs gained were calculated from 128 patients; the proportion of patients improved was calculated from
127 patients.
\High represents the upper 90% CI for the difference between groups, and Low represents the lower 90% CI for the difference between
groups.
**The base-case analysis included time loss from work. The sensitivity analysis included time loss from usual major activities also.
††A ratio will not be calculated as the cost of time loss was not included in the HCS perspective costs.
QALY=quality-adjusted life year; HCS=health care system; AC+H=Appropriate Care+hylan G-F 20; AC=Appropriate Care;
CI=confidence interval.
Osteoarthritis and Cartilage Vol. 10, No. 7 525statistically significantly so, by both the disease specific
measure (WOMAC), and by the health utility measure
(HUI3). The important outcomes for the economic analysis
were the incremental proportion of patients improved in the
AC+H group compared to the AC group (29%) and the
incremental QALYs gained in the AC+H group compared to
the AC group (0.071). The former outcome, 29%, exceeded
the a priori threshold for clinical importance which had been
set at 20%. However, no threshold had been established a
priori for an important increment in QALYs.
Is a mean gain of 0.071 QALYs per patient important?
One way to address this question, is to return to the theory
on which the HUI3 instrument is based, von Neumann–
Morgenstern utility theory and the standard gamble
measurement. On the basis of this theory a direct interpret-
ation is that a gain of 0.071 QALYs over a year is equivalent
to a reduction in mortality rate of 0.071. That is, providing
an ongoing improvement in quality of life of this magnitude
(0.071 QALY per year) is equivalent to finding a group of
healthy individuals (no HUI3 disabilities) who are at high
risk (50%) of immediate sudden death and providing them
with an absolute risk reduction in mortality of 7.1% (i.e.,
reducing their risk to 42.9%). If the group of individuals has
compromised quality of life like patients with knee OA, the
interpretation is even more dramatic. According to von
Neumann–Morgenstern utility theory a patient like those at
baseline in the AC+H group with a utility score of 0.50 and
no risk of immediate death would be willing to take a risk
of immediate death of 12.4%, 0.124=1.000−(0.500/
(0.500+0.071)), to achieve an ongoing improvement in
quality of life of 0.071. Thus, there is little question that a
QALY gain of this magnitude is important. Moreover, any
QALY gain can be important depending on the cost
required to produce the gain and on the overall context of
the gain21.
The cost-effectiveness finding is that the incremental
cost per patient improved over 1 year is $2505 (societal)
and $2488 (HCS). That is, an expenditure of approximately
$2500 will purchase an improved patient for a year. Is this
good value for money? There is no absolute answer.
Decision-makers responsible for allocating resources will
have to weigh this opportunity against other choices. If the
other choices are not expressed in the same metric,
improved patients, the comparison becomes difficult. This
highlights the advantage of cost–utility analysis.
The finding of the cost–utility analysis is that the incre-
mental cost per QALY gained is $10 000 (societal) and
$9930 (HCS). That is, an expenditure of approximately
$10 000 will purchase a gain of 1 QALY. Is this good value
for money? There are several ways to approach the ques-
tion. One approach is to compare the results to other
studies using a league table in which studies are ranked
from best to worst according to their cost per QALY gained.
Current methodological advice is that indiscriminate com-
parisons of this type can be misleading, and that league
tables should be restricted to high-quality studies that use
comparable scientific methods, and possibly further
restricted to interventions targeted at one condition (e.g.,
musculo-skeletal problems)22.
Chapman et al. from Harvard University undertook a
comprehensive literature review of cost–utility studies
1976–1997 and categorized them into ‘Panel-worthy’ or
not, and further subdivided the list by disease categories
one of which is musculo-skeletal23. ‘Panel-worthy’ studies
are those that met a minimum standard of methodological
quality established by Chapman et al. based on the recom-
mendations of the Panel on Cost-Effectiveness in Healthand Medicine24. There has been only one ‘Panel-worthy’
study in the field of musculo-skeletal diseases, a cost-
effectiveness analysis of total hip arthroplasty for OA of the
hip, published in 1996 by Chang et al. In addition, there is
a relevant ‘Panel-worthy’ study in the digestive system
category, a cost-utility analysis of the use of misoprostol
prophylaxis for rheumatoid arthritis patients receiving
NSAIDs drugs, published by Gabriel et al. in 1994. These
two studies contain four cost–utility ratios. The four ratios
are included in our league table (Table IV).
In addition we have included, for comparison, one rel-
evant Canadian study25. Although it did not meet the
criteria for ‘Panel-worthy’, we believe it can be usefully
interpreted. One shortcoming of the study, lack of discount-
ing, we have corrected in the data shown here using a
discount rate of 5% per year. Another shortcoming, lack of
incremental costing (they did not measure the costs that
would have occurred without hip replacement) was con-
servative. On the positive side, the study was Canadian
and, thus, is more directly comparable to our hylan G-F 20
study. The study prospectively measured costs (from the
perspective of the health care system) and time trade-off
utilities for total hip arthroplasty over 1 year, and modeled
the analysis for 2 additional years for a total analytic
horizon of 3 years.
For consistency with the Harvard table of ‘Panel-worthy’
studies, all entries in the league table (Table IV) have been
adjusted to 1998 US dollars. The two Canadian ratios were
first adjusted to 1998 Canadian dollars, using the Health
Care component of the Canadian Consumer Price Index26,
and then converted to US dollars using the mean exchange
rate for 1998, 1.483127. As shown in the league table, hylan
G-F 20 provides ‘value for money’, from either perspective,
that is not as good as total hip arthroplasty for 60-year-oldTable IV
Cost/QALY League Table (1998 US dollars)
Cost/QALY
gained
Treatment and comparator
Cost-saving Total hip arthroplasty vs no total hip arthroplasty
in white 60-year-old women with hip osteoarthritis
in American College of Rheumatology function
class III (significant functional limitation, but not
dependent)23
$5500 Total hip arthroplasty vs no total hip arthroplasty
in white men ≥85 years old with hip osteoarthritis
in American College of Rheumatology function
class III (significant functional limitation, but not
dependent)23
$6500 Appropriate Care+hylan G-F 20 vs Appropriate
Care for knee osteoarthritis, health care system
perspective (this study)
$6600 Appropriate Care+hylan G-F 20 vs Appropriate
Care for knee osteoarthritis, societal perspective
(this study)
$7500 Total hip arthroplasty vs no hip arthroplasty for all
patients, 3 year follow-up25
$11 000 Prophylaxis for NSAID-associated gastric ulcers
with low-dose misoprostol (100 mcg four times
daily) for elderly (>60 years old) vs no
prophylaxis for all NSAID users in rheumatoid
arthritis patients on NSAIDs23
$12 000 Prophylaxis for NSAID-associated gastric ulcers
with low-dose misoprostol (100 mcg four times
daily) for all vs prophylaxis for elderly (>60 years
old) in rheumatoid arthritis patients on NSAIDs23
526 G. W. Torrance et al.: Economic evaluation of hylan G-F 20 for knee OAUS women as studied by Chang et al., but is similar to total
hip arthroplasty for ≥85-year-old US men studied by Chang
et al. or for Canadians studied by Laupacis et al.25, and is
better than misoprostol prophylaxis for rheumatoid arthritis
patients taking NSAIDs.
A second approach to answering the question of value
for money is to compare the results to some external
standard. For example, Laupacis et al.20 suggest that if a
new therapy is more effective and more costly than the
existing one and costs less than $20 000/QALY gained,
there exists strong evidence for adoption of the new
therapy. Similarly, $20 000 to $100 000/QALY gained pro-
vides moderate evidence for adoption, and over $100 000/
QALY gained provides weak evidence for adoption. These
costs are in 1990 Canadian dollars, and the thresholds in
1999 dollars may be larger. Thus, the cost–utility results for
the use of hylan G-F 20 in the knee fall in the category of
strong evidence in favour of adoption.STUDY STRENGTHS
The study was designed according to rigorous standards
put forth in guidelines for economic evaluations. All of the
participating investigators had a high degree of experience
treating patients with hylan G-F 20, therefore it was poss-
ible to measure effectiveness, or ‘real world’ clinical effects,
the outcome required for an economic evaluation. Hylan
G-F 20 was compared to an appropriate comparator in that
current practice guidelines were employed rather than
placebo. The study was open-label and therefore physi-
cians could practice according to their normal routine. Both
treatment groups had equal access to the full repertoire of
appropriate care. It was possible to limit the amount of
protocol-driven costs by employing telephone interviews to
collect data. Costs included indirect and direct costs, and
overhead costs were included. The study time horizon was
1 year, which enabled measurement of downstream costs
and consequences associated with subsequent courses of
hylan G-F 20, adverse events, and treatment failure.STUDY LIMITATIONS
One of the limitations was that the study was open-label
and patients or physicians may have been biased in favour
of hylan G-F 20 treatment which in turn could have affected
outcomes and costs. On the other hand, many in the AC
group also received a knee injection (corticosteroid), and all
patients in both groups received appropriate care. The
ongoing telephone interviews may have influenced the
patient assessments. The patients might have improved
because of the attention they received, or they might have
felt worse because they focused more on their symptoms
when answering symptom questionnaires. However, the
potential telephone interview biases would have been simi-
lar in both groups, therefore it is unlikely there was a
differential from this source.GENERALIZABILITY
The study applies to patients treated by rheumatologists
and orthopedic surgeons in Canada. The results are not
directly applicable in other countries. Readers in other
countries have to decide which aspects of the study apply,
and which aspects need to be modified. It is generally felt
that clinical findings travel fairly well. One would expectsimilar findings in the patient outcomes—WOMAC scores,
SF-36 scores and HUI3 scores. Moreover, although the
HUI3 is scored based on preferences from a Canadian
population, there is considerable evidence that preference
scores from the general public are independent of country
(for example, see Johnson et al.28 and Gales et al.29). On
the other hand, because the health care systems differ
among countries, the utilization of health care resources
may differ. Moreover, the prices of health care resources
including hylan G-F 20 differ in different countries. Thus, the
costs can not be assumed to apply in other countries.
Those interested in other countries will have to modify the
study results appropriately30 or use this study as a proto-
type from which to conduct a study in their own country.Conclusions
This study demonstrates that hylan G-F 20, when used
in conjunction with appropriate care, provides an improve-
ment in outcomes that is both clinically important and
statistically significant. Total costs are higher when hylan
G-F 20 is selected as a treatment option for patients with
OA of the knee, but the cost per QALY gained is well below
the suggested Canadian threshold for adoption.Acknowledgments
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AC+H=Appropriate care with hylan G-F 20
AC=Appropriate care without hylan G-F 20
WOMAC=Western Ontario and McMaster Universities
Osteoarthritis Index
HUI3=Health Utilities Index 3
QALYs=quality-adjusted life years
OA=osteoarthritis
HRQOL=Health-related quality of life
CRO=contract research organization
NSAIDs=non-steroidal antiinflammatory drugs
SF-36=Short-Form 36
HCS=health care system
$Can=Canadian dollars
ER=emergency room
ICD9-CM=international classification of disease ninth
revision clinical modification
CEA=cost-effectiveness analysis
CUA=cost-utility analysis
